Patent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues

Concerns over the availability of affordable health care have focused national attention upon patents and other intellectual property rights awarded to pharmaceutical firms. Legislation that was introduced before, but not enacted by, the 112th Congress proposed amendments to the Hatch- Waxman Act, legislation dating from 1984 that governs intellectual property rights in pharmaceuticals and other regulated products. Recent rulings from the federal judiciary regarding the Hatch-Waxman Act may be pertinent to future congressional consideration of that statute. Both the judicial holdings, as well as possible legislative changes to the Hatch-Waxman Act, potentially affect the availability of both brand-name and generic drugs in the United States. The Hatch-Waxman Act includes two core provisions that impact the enforcement of patent rights by brand-name firms against generic pharmaceutical companies. 35 U.S.C. §271(e)(1) creates a statutory "safe harbor" that exempts firms from claims of patent infringement based on clinical trials and other acts reasonably related to seeking marketing approval from the Food and Drug Administration (FDA). The explicit wording of that statute does not preclude activities that occur after the receipt of FDA marketing approval from the "safe harbor." Two recent opinions from the U.S. Court of Appeals for the Federal Circuit are arguably in tension over whether post-approval acts are exempted from infringement, however.


This package includes following files:

#	File Name	Document Date	Order ID:	Number of Pages	Price
1	R42354.pdf	Jan 17, 2013	R42354	10	$29.95	Add to Cart

Older Versions:

Patent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues  [Order No: R42354  Release Date: Feb 09,2012  Pages: 9]